Introduction
Despite the success of antiretroviral therapy (ART) in lowering mortality of people living with HIV, 31 some individuals still experience virological failure (VF) on their ART regimen. Given the large 32 number of potential anti-HIV drugs available, an effective second-or third-line salvage regimen 33 consisting of new drugs from different drug classes can generally be prescribed [1] . However, for a 34 minority of individuals it is sometimes difficult to construct a salvage regimen because of extensive 35 and complex resistance patterns or, in resource-limited settings (RLS), because of limited drug 36 availability, infrequent or absent viral load monitoring and a consequent lack of timely switching. In 37 these situations, clinicians may be forced to keep individuals on their failing regimen for extended 38 periods of time [2, 3] . 39 
40
Individuals who are kept on a failing ART regimen can still derive clinical benefit from the treatment 41 and may experience stable or increasing CD4 counts despite ongoing viral replication [4] [5] [6] . This has 42 been hypothesised to reflect lower replicative capacity of viruses with drug resistance mutations 43 (DRM), particularly for the mutation M184V selected for by lamivudine [7] . However, other factors 44 such as reduced CD4 cell turnover and/or activation [8] , the inhibition of CD4 cell apoptosis by 45 protease inhibitors (PI) [9] , ineffective replication in the thymus by PI resistant viruses [10] or 46 residual antiviral activity [11] have also been proposed as potential explanations. Although 47 for VL as a continuous, time-updated covariate on the log10 scale. For the baseline table we also 105 present data on the level of viral suppression. This was estimated by comparing current VL levels 106 with an individual's viral set point, which was defined as the mean of all pre-ART VL measures. 107
108
We adjusted the p-values derived from the analysis of individual DRM for multiple testing, as these 109
were chosen based on a prevalence threshold and not an a-priori hypothesis. To do this we used the 110
Benjamini-Hochberg procedure for correcting the false discovery rate (FDR) [29] , which produces a 111 q-value representing the probability of a significant finding being a false positive. We used a q-value 112 threshold of 0.05 to indicate significant results. 113
Results

115
Characteristics of the study population 116
A total of 5,357 individuals contributing 7,661 VF episodes were included in the analyses; 2,757 117 (36%) from EuroSIDA and 4,904 (64%) from UK CHIC. Individuals experienced a median of 1 118 (range=1-9) VF episodes, which lasted for a median of 5 (inter-quartile range [IQR]=2-13) months 119
and contained a median of 3 (IQR=2-5) CD4 measurements. The characteristics of the population at 120 the start of each episode can be seen in the supplementary materials, S3. Although 15.6% of 121 episodes occurred while individuals were on mono/dual therapy, the majority occurred while 122 individuals were in receipt of more than 3 drugs. The most common type of cART was NNRTI based 123 (19.8%) . 56% of episodes occurred while individuals were receiving lamivudine. The second most 124 common drug was tenofovir (30%) followed by indinavir (33%). 1,338 different combinations of 125 drugs were used, the most common being zidovudine, lamivudine and nevirapine. A description of 126 all drugs utilised can be found in the supplementary materials (S4). 127
128
Any resistance was detected in 6,804/7,661 episodes (88.8%). The prevalence of any NRTI resistance 129 was 68.0%, any NNRTI resistance 58.2% and any PI resistance (excluding minor PI mutations) 51.0%. 130
The prevalence of the 55 distinct RT mutations and 64 PI mutations that were detected at a 131 frequency of more than 1% can be seen in Figure 1 . There were some differences in host and viral 132 characteristics between episodes where resistance was detected compared to episodes where it was 133 not (Supplementary materials, S3). Notably, episodes with no resistance had higher baseline viral 134 load values (p<0.001). The baseline viral load values were also more likely to be higher than set-135 point estimates in episodes with no detected resistance (p<0.001). However, there was only very 136 weak evidence suggesting a difference in CD4 counts measured at the start of episodes (p=0.05). 137
CD4 count changes over time and according to the detection of any and class resistance 138
In univariable analysis, the estimated CD4 cell decline during episodes of VF was 20 cells/mm 3 /year 139 in the entire population. CD4 cell declines were less steep (although still notable) 140 when time-updated VL levels were below pre-ART set-point values (p=0.008; data not shown). 141 Figure 2 shows the estimated difference in annual CD4 cell decline according to the detection of any 142
and class of resistance. CD4 counts declined less rapidly during episodes where drug resistance was 143 detected compared to episodes where resistance was not detected, with an estimated difference of 144 28 (-17 [-20; -15] v -46 [-56; -36] ) cells/mm 3 /year, interaction p<0.001). 145
These findings persisted after adjustment for the pre-specified confounders (difference=28 146 cells/mm 3 /year, p<0.001) and after further adjustments for VL (difference=32 where NRTI resistance was detected compared to episodes where NRTI resistance was not detected 151 (-15 (-18; -12) v -40 (-48; -33) cells/mm 3 /year, interaction p<0.001). Adjustment for pre-specified 152 confounders and VL did not change the difference in CD4 cell slopes between those with and 153 without NRTI resistance markedly (difference=27 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and 28 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Figure 2 ). There was also evidence that CD4 counts declined faster during episodes 155 where NNRTI resistance was detected in both univariable analyses (-22 (-26; -19) v -10 (-15; -5) 156 cells/mm 3 /year, interaction p<0.001) and after both adjustments (Figure 2) . 157
158
There was no evidence to suggest that CD4 cell decline differed according to the detection of PI 159 resistance including minor PI mutations (Error! Reference source not found. 2). However, there was 160 some weak evidence suggesting that CD4 cell decline was less steep during episodes where major PI 161 mutations were detected, both in univariable (difference=6 (-1-12) The effect of specific DRM on CD4 count changes 166
The difference in CD4 cell decline between episodes with and without a given RT mutation after 167 adjustment for pre-specified confounders is shown in Figure 3 . After correcting for multiple testing, 168 the strongest association was found for M184V, with episodes where M184V was detected 169 experiencing somewhat less steep CD4 cell declines (difference= 17 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) cells/mm3/year, 170 q<0.001). These findings did not change markedly after additional adjustment for VL (difference=16 171 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) cells/mm3/year, q<0.001, Supplementary Materials, S5). There was also reasonable 172 evidence that the T215Y and D67N mutations were associated with less steep CD4 cell declines both 173 before (difference=11 (5-17) and 11 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) respectively, both p=0.012) and after (difference=10 (4-174 16 ) and 12 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , q=0.019 and 0.003 respectively) adjustment for VL. One NNRTI mutation, V179D, 175 was associated with steeper CD4 declines, although the confidence intervals surrounding this finding 176 were very wide (difference=-44 (-69; -19) cells/mm3/year, q=0.012, Figure 3 ). There was also some 177 very weak evidence (q=0.05) suggesting that those with the L74V mutation experienced somewhat 178 steeper CD4 declines, but the evidence supporting this finding disappeared upon adjustment for VL 179 (Supplementary Materials, S5) . 180 181 Of the PI mutations studied, 2 remained associated with a less steep CD4 decline after correction for 182 multiple testing: V82A and I54V (Figure 4) . The strongest association was found for the V82A 183 mutation, where CD4 decline was estimated to be 18 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) cells/mm3/year less steep during 184 episodes where the mutation was detected compared to episodes without the mutation (q<0.001). 185 CD4 decline was also 13 (5-20) cells/mm3/year less steep during episodes where I54V was detected 186 (q=0.015). Again, further adjustment for VL did not change these conclusions or shift the point 187 estimates notably (Supplementary Materials, S5) . 188
Clusters of mutations 189
The PCA analysis identified five RT and two PR clusters. The process by which they were selected is 190 described in more detail in the Supplementary Materials (S1). Briefly, the first three RT clusters 191 corresponded roughly to the TAM mutations (RT codons 210, 41, 215, 219, 67, 70 plus 44, and 118) two PR clusters, the first consisted primarily of major PI mutations (codons 46, 48, 54, 58, 82, 84 and 196 90) with some minor PI mutations (codons 10, 24, 33, 53, 64, 71and 73) 
Discussion
215
Although the aim of HIV treatment should always be to suppress the VL to undetectable levels, there 216 is a minority of patients with extensive resistance or without access to any other drug options for 217 whom this is not possible. Composing a salvage regimen for these individuals presents a particular 218 challenge, and it has long been debated whether including drugs that preserve resistance patterns 219 associated with lower viral fitness may provide some clinical benefit [4, 6, 30] . In this analysis, we 220 found that among individuals maintained on a failing treatment regimen, CD4 counts declined less 221 rapidly during episodes in which resistance was detected compared to episodes where resistance 222 was not detected. DRM detection can serve as a proxy for ongoing ART pressure and at least partial 223 antiviral activity, whereas the absence of DRM can indicate high levels of non-adherence. VF 224 episodes with no detected DRM had much higher baseline VL levels in addition to more rapid CD4 225 cell decline, which supports the hypothesis that those individuals without DRM may not be taking 226 their ART. When restricting the analyses to episodes with any detected resistance, CD4 counts 227 decreased less steeply during episodes of virological failure where any NRTI resistance, the RT 228 mutations M184V, D67N and T215Y and either of the PR mutations V82A and I54V were detected. 229 CD4 counts declined more steeply during episodes with detected NNRTI resistance, as well as the RT 230 mutations V179D and, marginally, L74V. 231 232 It has been suggested that differences in CD4 cell decline according to the presence of certain DRM 233 could reflect differences in the replicative capacity of the virus [31] . The M184V mutation in the 234 reverse transcriptase has been frequently shown to adversely impact replicative capacity [32] [33] [34] [35] , 235 and the T215Y mutation has been associated with an impaired RC [35, 36] . In contrast, D67N has 236 been found to have relatively high RC [31, 36] . The V82A mutation has been reported to negatively 237 impact the functionality of the viral protease which could lead to a lower RC [37] . However, 238 adjustment for VL, which is associated with the replicative capacity of a virus [14] , did not affect the 239 conclusions or the size of the CD4 cell decline markedly in this analysis. Although this could indicate 240 that the effects described here are not being mediated through viral load changes, a model 241 adjusting for a mediating variable often fails to accurately estimate the total direct effect of the 242 exposure on the outcome [38] [39] [40] . It is possible that adjusting for time-updated VL has not removed 243 the effect that might be mediated through this variable, and this limitation should be born in mind 244 when interpreting the results. 245
246
The results from studying clusters of mutations indicated that episodes where the mutation pattern 247 broadly aligned with TAM-2 mutations or the broad PI resistance described by the 1 st PI cluster had 248 less steep CD4 cell declines. Although the TAM-2 mutations D67N, K70R and K219Q have relatively 249 low fitness costs when present alone [31] , the presence of K70R has been shown to result in 250 reduction in fitness when it emerges in viruses carrying both D67N and K219Q in the absence of drug 251 pressure [41] . Such a combined effect may also explain why the detection of each of these 3 252 mutations individually resulted in less steep CD4 cell declines, although only significantly so for the 253 D67N mutation after correcting for multiple testing. The impact of PI resistance on replicative 254 capacity is complex to predict as these mutations may be accompanied by compensatory PI 255 mutations that can restore viral fitness [31] . However, it is possible that the first PI cluster could 256 capture the effect of a number of major PI mutations which, when present in combination, could be 257 associated with favourable CD4 cell changes. We also found weak evidence that the fourth RT 258 cluster was associated with steeper CD4 cell declines. The mutations that formed part of this cluster 259 include K103N and L100I, both of which have been shown to have a very small fitness cost [31] . 260 261 Previous studies of the effect of drug resistance on CD4 cell changes have found conflicting results. A 262 previous randomised trial, COLATE, which evaluated continuation versus discontinuation of 263 lamivudine in individuals with VF as compared to other cART in order to study the effect of 264 preserving the M184V/I mutation, failed to demonstrate a virological or immunological benefit of 265 continuing lamivudine [30] . The authors suggested that this could be due to the high GSS of the 266 switch regimens, which could be masking any potential benefits. An earlier pilot trial (E-184V) 267 reported a benefit of lamivudine monotherapy compared to treatment interruption in treatment 268 experienced patients on HAART requesting a treatment interruption, and suggested that these 269 benefits are in part due to the preservation of M184V [6] . Recently presented results from the 270 MOBIDIP/ ANRS 12286 trial have also shown a marked clinical benefit of using lamivudine in 271 combination with a boosted PI compared to the use of a boosted PI alone as a simplification strategy 272 for patients with a suppressed VL on second line therapy [42] . The findings from observational 273 studies have also been conflicting. In broad agreement with the findings presented here, a recent 274 analysis by Hoffman et al of a large cohort of people living with HIV from South Africa found that 275 CD4 counts declined less rapidly during episodes of persistent viraemia where M184V was detected, 276
although not significantly so (p=0.1) [43] . A study by Antinori et al in 2001 found that both M184V 277 and V82A were associated with immunological recovery despite ongoing viral replication in 278 univariable analyses, but not after adjustments for confounders including VL [20] . This is similar to 279 results reported by Gianotti et al, who found no associations between individual mutations in the 280 pol gene region and the odds of discordant immuno-virological responses when studying 825 281 individuals from the large ARCA database in Italy [19] . 282 283 There are several important limitations of our findings. Firstly, we did not have a validated measure 284 of adherence available, which unfortunately meant that we were not able to adjust for poor 285 adherence. Adherence has the potential to be an important confounder in this analysis, as it is likely 286 to influence both the presence of resistance and CD4 cell decline [44] . Although sensitivity analyses 287 where we excluded individuals with potentially poor adherence based on their VL trajectories led to 288 consistent results (data available on request), it is possible that this did not accurately identify poorly 289 adherent individuals. Secondly, many different drug combinations were used to treat individuals in 290 this study, and it was not possible to study the effect of individual regimens. Although adjustment 291 for current VL should remove the effect of residual antiviral activity exerted through the VL, we 292 cannot rule out that some of the different regimens used exerted some residual antiviral activity 293 that could explain some of the findings. Although we conducted sensitive analyses where we 294 adjusted for the class of drug received which showed consistent results (results available within the 295 supplementary materials, S4), we cannot rule out that adjustment for the specific regimen received 296 would produce different results due to the presence of residual confounding in our study. Future 297 studies conducted in other settings may have greater homogeneity in the types of regimens used, 298 and in these situations it would be of great interest to repeat the analyses stratified by the type of 299 regimen received. In addition, we cannot rule out that the results would differ in settings where 300 other subtypes predominate. Repeating the analyses within cohorts with a higher prevalence of non-301 B subtypes would be of great interest. Finally, despite using combined data from two large cohorts, 302 the relatively low prevalence of individual mutations means that some of our estimates, particularly 303 for rare mutations, suffer from low precision. 304
305
Bearing these limitations in mind, our findings provide some support for the hypothesis that CD4 cell 306 decline may be less marked when individuals experiencing VF are maintained on regimens that 307 preserve specific mutations that have previously been associated with reduced viral fitness. This 308 could have implications for individuals in RLS who have failed all existing available lines, and suggests 309 that in these instances the inclusion of lamivudine/emtricitabine and a boosted PI may be the best 310 option in terms of composing a salvage regimen. However, the likely effect of the presence of a 311 particular mutation on annual CD4 cell decline is likely to be relatively small and complex to predict 312 due to the presence of epistatic interactions and potentially confounding effects which are hard to 313 measure, such as residual drug action and adherence. Further research is needed to evaluate the 314 clinical benefits of specific treatment strategies that aim to preserve particular resistance patterns 315 among individuals for whom a potent ART regimen cannot be prescribed, as well as to elucidate the 316 mechanisms through which any beneficial effect is mediated. Until then, efforts should focus on 317 ensuring that those who experience VF have access to individualised care and a broad range of 318 antiretroviral drugs, and, where possible, novel ART drugs through compassionate early access 319 programs to allow the construction of fully suppressive regimens. 320
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